Arlington Medical Resources (AMR) and Decision Resources find that availability in both intravenous and oral formulation is a leading drug attribute that surveyed physicians prefer for the treatment of complicated urinary tract infections (UTIs) in the hospital setting. Antibiotics available in interchangeable oral and parenteral formulations can facilitate step-down therapy and discharge from the hospital to the outpatient setting.

"Physicians prescribe a wide variety of antibiotics for UTIs, mainly from the quinolone and cephalosporin classes," stated Lisa Arias, analyst at Decision Resources. "These broad-spectrum agents are popular first-line agents in UTIs, and oral quinolones, in particular, have become a popular choice for first-line, step-down and discharge therapy."

The new report entitled Hospital Anti-Infectives Insight Series: Urinary Tract Infections also finds that extended-spectrum beta-lactamase-producing and quinolone-resistant gram-negative pathogens are among the most concerning pathogens, and that 77 percent of surveyed physicians expect to increase their prescribing of carbapenems for complicated UTIs in the next five years. These potent, broad-spectrum antibiotics are especially useful for treating gram-negative infections involving resistant organisms.

About Hospital Anti-Infectives Insight Series

AMR and Decision Resources' Hospital Anti-Infectives Insight Series analyzes hospital antibiotic prescribing patterns using AMR's comprehensive and highly detailed clinical data in conjunction with Decision Resources' disease area knowledge, primary research and extensive understanding of emerging therapies and forecasts. These reports examine the reasons behind physicians' product preferences, factors driving hospital antibiotic prescribing patterns and receptivity to emerging antibiotics.

About AMR

AMR (www.AMR-data.com) serves the market intelligence needs of the pharmaceutical and diagnostic imaging industries. Research includes clinical inpatient databases that directly link anti-infective drug with indication/procedure, formulary and stocking status tracking studies, drug purchasing audits and diagnostic imaging procedure volume/contrast media usage audits. AMR is a Decision Resources, Inc. company.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:   Gisselle Morales   Decision Resources   781-296-2691   gmorales@dresources.com    Elizabeth Marshall   Decision Resources, Inc.   781-296-2563   emarshall@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources; Arlington Medical Resources

CONTACT: Gisselle Morales, +1-781-296-2691, gmorales@dresources.com, or
Elizabeth Marshall, +1-781-296-2563, emarshall@dresources.com, both of
Decision Resources, Inc.

An Increase in the Diagnosed Prevalent Population Will Drive Growth of Nearly $4.3 Billion in the Chronic Obstructive Pulmonary Disease Market

View Now